Nivolumab for Squamous-Cell Cancer of Head and Neck

To the Editor: A new class of toxic effects has emerged with cancer immunotherapy. Endocrine immune-related adverse events are especially interesting because they are frequent but rarely require the discontinuation of treatment. Moreover, immunotherapy offers a promising model for the study of some...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 376; no. 6; pp. 595 - 596
Main Authors González-Rodríguez, Elisa, Rodríguez-Abreu, Delvys, Boronat, Mauro, Bins, Sander, van Meerten, Esther, Mathijssen, Ron H.J, Ferris, Robert, Gillison, Maura L
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 09.02.2017
Subjects
Cancer
Cancer immunotherapy
Carcinoma, Squamous Cell
Clinical trials
Endocrine disorders
Head & neck cancer
Head and Neck Neoplasms
Humans
Immunotherapy
Monoclonal antibodies
Neck
Targeted cancer therapy
Thyroid gland
Online AccessGet full text

Cover

More Information
Summary:To the Editor: A new class of toxic effects has emerged with cancer immunotherapy. Endocrine immune-related adverse events are especially interesting because they are frequent but rarely require the discontinuation of treatment. Moreover, immunotherapy offers a promising model for the study of some autoimmune endocrinopathies that are rare in the general population and whose pathophysiological mechanisms are not fully known. In this regard, precise definitions of endocrine immune-related adverse events in immunotherapy trials are a pending issue in this field. Ferris et al. (Nov. 10 issue) 1 report the results of nivolumab treatment in patients with squamous-cell carcinoma of the head . . .
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ObjectType-Commentary-2
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMc1615565